These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12483109)

  • 1. Update in childhood acute myeloid leukemia: recent developments in the molecular basis of disease and novel therapies.
    Clark JJ; Smith FO; Arceci RJ
    Curr Opin Hematol; 2003 Jan; 10(1):31-9. PubMed ID: 12483109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in pediatric acute lymphoblastic and myeloid leukemia.
    Ravindranath Y
    Curr Opin Oncol; 2003 Jan; 15(1):23-35. PubMed ID: 12490758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyotype and are unrelated to type of previous therapy.
    Christiansen DH; Pedersen-Bjergaard J
    Leukemia; 2001 Dec; 15(12):1848-51. PubMed ID: 11753604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia.
    Christiansen DH; Andersen MK; Desta F; Pedersen-Bjergaard J
    Leukemia; 2005 Dec; 19(12):2232-40. PubMed ID: 16281072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor.
    Chillón MC; Fernández C; García-Sanz R; Balanzategui A; Ramos F; Fernández-Calvo J; González M; Miguel JF
    Hematol J; 2004; 5(3):239-46. PubMed ID: 15167911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.
    Goemans BF; Zwaan CM; Miller M; Zimmermann M; Harlow A; Meshinchi S; Loonen AH; Hählen K; Reinhardt D; Creutzig U; Kaspers GJ; Heinrich MC
    Leukemia; 2005 Sep; 19(9):1536-42. PubMed ID: 16015387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the treatment of acute leukemia: 1999.
    Berman E
    Curr Opin Hematol; 2000 Jul; 7(4):205-11. PubMed ID: 10882175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of acute myeloid leukemia: state-of-the-art and future directions.
    Stone RM
    Semin Hematol; 2002 Jul; 39(3 Suppl 2):4-10. PubMed ID: 12214287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delineation and molecular characterization of acute myeloid leukemia patients with coduplication of FLT3 and MLL.
    Olesen LH; Nyvold CG; Aggerholm A; Nørgaard JM; Guldberg P; Hokland P
    Eur J Haematol; 2005 Sep; 75(3):185-92. PubMed ID: 16104873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FLT3 and its role in the pathogenesis of acute myeloid leukaemia.
    Reilly JT
    Leuk Lymphoma; 2003 Jan; 44(1):1-7. PubMed ID: 12691136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting transcription factors in acute leukemia in children.
    Berman JN; Look AT
    Curr Drug Targets; 2007 Jun; 8(6):727-37. PubMed ID: 17584028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of childhood acute myeloid leukemia.
    ter Bals E; Kaspers GJ
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):917-29. PubMed ID: 16221060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular events in follicular thyroid tumors.
    Kroll TG
    Cancer Treat Res; 2004; 122():85-105. PubMed ID: 16209039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute myeloid leukemia: advances in diagnosis and classification.
    Hasserjian RP
    Int J Lab Hematol; 2013 Jun; 35(3):358-66. PubMed ID: 23590662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
    Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM
    Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical importance of cytogenetics in acute myeloid leukaemia.
    Mrózek K; Heinonen K; Bloomfield CD
    Best Pract Res Clin Haematol; 2001 Mar; 14(1):19-47. PubMed ID: 11355922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FLT3 as a therapeutic target in childhood acute leukemia.
    Stubbs MC; Armstrong SA
    Curr Drug Targets; 2007 Jun; 8(6):703-14. PubMed ID: 17584026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting receptor tyrosine kinase signaling in acute myeloid leukemia.
    Doepfner KT; Boller D; Arcaro A
    Crit Rev Oncol Hematol; 2007 Sep; 63(3):215-30. PubMed ID: 17658267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tandem duplications of MLL and FLT3 are correlated with poor prognoses in pediatric acute myeloid leukemia: a study of the Japanese childhood AML Cooperative Study Group.
    Shimada A; Taki T; Tabuchi K; Taketani T; Hanada R; Tawa A; Tsuchida M; Horibe K; Tsukimoto I; Hayashi Y
    Pediatr Blood Cancer; 2008 Feb; 50(2):264-9. PubMed ID: 17763464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.